MedTrace Logo

ERG/EOG Study in AMD Patients Treated With Ranibizumab

NCT00791427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2015-05-08

No results posted yet for this study

Summary

This is an open-label study assessing electrophysiologic testing of the retina with Electoretinogram (ERG) /Electrooculogram (EOG) tests in patients with exudative age-related macular degeneration (AMD). The standard FDA-approved treatment for wet AMD is ranibizumab (Lucentis). This study focuses on the ERG and EOG tests to evaluate retinal responses to ranibizumab treatment in AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Ranibizumab

0.05 ml of ranibizumab injected into the eye monthly for one year

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Retina Center, Minnesota

    lead OTHER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791427 on ClinicalTrials.gov